Antibody Glycosylation

Post-translational Modification of Protein Biopharmaceuticals

Volumn , Issue , 2009, Pages 79-108

  Jefferis, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antibodies; Glycosylation; Human IgG; IgG Fc; Translational medicine

Indexed keywords

EID: 81355139831     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626601.ch4     Document Type: Chapter

References (148)

1. Baker, M. (2005) Upping the ante on antibodies. Nature Biotechnology, 23, 1065-1072.
2. Reichert, J.M. et al. (2005) Monoclonal antibody successes in the clinic. Nature Biotechnology, 23, 1073-1078.
3. Carter, P.J. (2006) Potent antibody therapeutics by design. Nature Reviews, 6, 343-357.
4. Satoh, M., Iida, S., Shitara, K. (2006) Nonfucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opinion on Biological Therapy, 6, 1161-1173.
5. Ledford, H. (2007) Biotechs go generic: the same but different. Nature, 449, 274-276.
6. Woodcock, J. et al. (2007) The FDA's assessment of follow-on protein products: a historical perspective. Nature Reviews. Drug Discovery, 6, 437-442.
7. Schellenkens, H. (2008) The first biosimilar epoetin: but how similar is it? Clinical Journal of the American Society of Nephrology, 3, 174-178.
8. Liang, P.H. et al. (2008) Glycan arrays: biological and medical applications. Current Opinion in Chemical Biology, 12, 86-92.
9. Freeze, H.H. (2007) Genetic defects in the human glycome. Nature Reviews.Genetics, 7, 537-551.
10. Jefferis, R. (2005) Glycosylation of recombinant antibody therapeutics. Biotechnology Progress, 21, 11-16.
11. Jefferis, R. (2007) Antibody therapeutics: isotype and glycoform selection. Expert Opinion on Biological Therapy, 7, 1401-1413.
12. Vanhooren, V. et al. (2007) N-Glycomic changes in serum proteins during human aging. Rejuvenation Research, 10, 521-531.
13. Alavi, A. and Axford, J.S. (2006) The pivotal nature of sugars in normal physiology and disease. Wiener Medizinische Wochenschrift, 156, 19-33.
14. Holland, M. et al. (2006) Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA associated systemic vasculitis. Biochimica et Biophysica Acta, 1760, 669-677.
15. Poland, D.C. et al. (2005) Activated human PMN synthesize and release a strongly fucosylated glycoform of {alpha}1-acid glycoprotein, which is transiently deposited in human myocardial infarction. Journal of Leukocyte Biology, 78, 453-461.
16. Smalling, R. et al. (2004) Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnology Annual Review, 10, 37-50.
17. Sinclair, A.M. and Elloitt, S. (2005) Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. Journal of Pharmaceutical Sciences, 94, 1626-1635.
18. Walsh, G. and Jefferis, R. (2006) Posttranslational modifications in the context of therapeutic proteins. Nature Biotechnology, 24, 1241-1252.
19. Raju, T.S. et al. (2000) Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology, 10, 477-486.
20. Van den Nieuwenhof, I.M. et al. (2000) Recombinant glycodelin carrying the same type of glycan structures as contraceptive glycodelin-A can be produced in human kidney 293 cells but not in Chinese hamster ovary cells. European Journal of Biochemistry, 267, 4753-4762.
21. Lienard, D. et al. (2007) Pharming and transgenic plants. Biotechnology Annual Review, 13, 115-1147.
22. Birch, J.R. and Racher, A.J. (2006) Antibody production. Advanced Drug Delivery Reviews, 58, 671-685.
23. Quan, C. et al. (2008) A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Analytical Biochemistry, 373, 179-191.
24. Harris, R.J. (2005) Heterogeneity of recombinant antibodies: linking structure to function. Developmental Biology, 122, 117-127.
25. Burton, D.R. and Woof, J.M. (1992) Human antibody effector function. Advances in Immunology, 51, 1-84.
26. Woof, J.M. and Burton, D.R. (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Reviews. Immunology, 4, 89-99.
27. Nezlin, R. and Ghetie, V. (2004) Interactions of immunoglobulins outside the antigen-combining site. Advances in Immunology, 82, 155-215.
28. Arnold, J.N. et al. (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annual Review of Immunology, 25, 21-50.
29. Deisenhofer, J. (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-Å resolution. Biochemistry, 20, 2361-2370.
30. Routier, F.H. et al. (1998) Quantitation of human IgG glycoforms isolated from rheumatoid sera: A critical evaluation of chromatographic methods. Journal of Immunological Methods, 213, 113-130.
31. Masuda, K. et al. (2000) Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Letters, 473, 349-357.
32. Mimura, Y. et al. (2007) Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. Journal of Immunological Methods, 326, 116-126.
33. http://glycomics.scripps.edu/CFGnomenclature.pdf. Accessed January 5th 2009.
34. Crispin, M., Stuart, D.I., Jones, E.Y. (2007) Building meaningful models of glycoproteins. Nature Structural & Molecular Biology, 14, 354-355.
35. http://www.functionalglycomics.org. Accessed January 5th 2009.
36. www.proglycan.com. Accessed January 5th 2009.
37. Yamada, E. et al. (1997) Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconjugate Journal, 14, 401-405.
38. Williams, P.J., Arkwright, P.D. and Rudd, P.M. (1995) Short communication: Selective transport of maternal IgG to the foetus. Placenta, 16, 749-756.
39. Kibe, T. et al. (1996) Glycosylation and placental transport of immunoglobulin G. Journal of Clinical Biochemistry and Nutrition, 21, 57-63.
40. Ferrara, C. et al. (2006) The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to nonfucosylated IgG glycoforms. The Journal of Biological Chemistry, 281, 5032-5036.
41. Farooq, M. et al. (1997) Glycosylation of antibody molecules in multiple myeloma. Glycoconjugate Journal, 14, 489-492.
42. Lund, J. et al. (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human FcgRI and influence the synthesis of its oligosaccharide chains. Journal of Immunology, 157, 4963-4969.
43. Sondermann, P. et al. (2000) The 3.2-A crystal structure of the human IgG1 Fc-FcgRIII complex. Nature, 406, 267-273.
44. Radaev, S. et al. (2001) The structure of human type FcgIII receptor in complex with Fc. The Journal of Biological Chemistry, 276, 16469-16477.
45. Padlan, E.A. (1990) Fc Receptors and the Action of Antibodies (ed. H. Metzger), American Society for Microbiology, Washington D.C., pp. 12-30.
46. Edelman, G.M. et al. (1969) The covalent structure of an entire IgG molecule. Proceedings of the National Academy of Sciences of the, United States of America 63, 78-85.
47. Mimura, Y. et al. (2000) The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Molecular Immunology, 37, 697-706.
48. Mimura, Y. et al. (2001) The role of oligosaccharide residues of IgG1-Fc in FcgIIb binding. The Journal of Biological Chemistry, 276, 45539-45547.
49. Krapp, S. et al. (2003) Structural analysis of human IgG glycoforms reveals a correlation between oligosaccharide content, structural integrity and Fcgreceptor affinity. Journal of Molecular Biology, 325, 979-989.
50. Yamaguchi, Y. et al. (2006) Glycoformdependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochimica et Biophysica Acta, 1760, 693-700.
51. Oganesyan, V. et al. (2008) Structural characterization of a mutated, ADCCenhanced human Fc fragment. Molecular Immunology, 45, 1872-1882.
52. Nimmerjahn, F. and Ravetch, J. (2007) Fcreceptors as regulators of immunity. Advances in Immunology, 96, 179-204.
53. Nimmerjahn, F. and Ravetch, J. (2008) Fcgamma receptors as regulators of immune responses. Nature Reviews. Immunology, 8, 34-47.
54. Edberg, J.C. and Kimberly, R.P. (1997) Cell type-specific glycoforms of Fcgamma RIIIa (CD16): differential ligand binding. Journal of Immunology, 159, 3849-3857.
55. Drescher, B., Witte, T., Schmidt, R.E. (2003) Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity. Immunology, 110, 335-340.
56. Malhotra, R. et al. (1995) Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Medicine, 1, 237-243.
57. Abadeh, S. et al. (1997) Remodelling the oligosaccharide of human IgG antibodies: effects on biological activities. Biochemical Society Transactions, 25, S661.
58. Wright, A. and Morrison, S.L. (1998) Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. Journal of Immunology, 160, 3393-3402.
59. Arnold, J.N. et al. (2005) Human serum IgM glycosylation: identification of glycoforms that can bind to mannanbinding lectin. The Journal of Biological Chemistry, 280, 29080-29087.
60. Terai, I. et al. (2006) Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannose-binding lectin. Journal of Immunology, 177, 1737-1745.
61. Dong, X., Storkus, W.J., Salter, R.D. (1999) Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. Journal of Immunology, 163, 5427-5434.
62. Wright, A. et al. (2000) In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology, 10, 1347-1355.
63. Garred, P., Michaesen, T.E., Aase, A. (1989) The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scandinavian Journal of Immunology, 30, 379-382.
64. Lucisano Valim, Y.M. and Lachmann, P.J. (1991) The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clinical and Experimental Immunology, 84, 1-8.
65. Voice, J.K. and Lachmann, P.J. (1997) Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. European Journal of Immunology, 27, 2514-2523.
66. Armour, K.L. et al. (2002) The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochemical Society Transactions, 30, 495-500.
67. Nandakumar, K.S. et al. (2007) Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. European Journal of Immunology, 37, 2973-2982.
68. Tao, M.H. and Morrison, S.L. (1989) Studies of aglycosylated chimeric mousehuman IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. Journal of Immunology, 143, 2595.
69. Pound, J.D., Lund, J., Jefferis, R. (1993) Aglycosylated chimeric human IgG3 can trigger the human phagocyte respiratory burst. Molecular Immunology, 30, 469-478.
70. Lund, J. et al. (1991) Human FcgRI and FcgRII interact with distinct but overlapping sites on human IgG. Journal of Immunology, 147, 2657-2662.
71. Sarmay, G. et al. (1992) Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of Fcg receptor. Molecular Immunology, 29, 633-639.
72. Shields, R.L. et al. (2001) High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. The Journal of Biological Chemistry, 276, 6591-6604.
73. Desjarlais, J.R. et al. (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discovery Today, 12, 898-910.
74. Radaev, S. and Sun, P. (2002) Recognition of immunoglobulins by Fcgamma receptors. Molecular Immunology, 38, 1073-1083.
75. Sauer-Eriksson, A.E. et al. (1995) Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure, 3, 265-278.
76. Corper, A.L. et al. (1997) Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nature Structural Biology, 4, 374-381.
77. Brambell, F.W.R., Hemmings, W.A. and Morris, I.G. (1964) A theoretical model of gammaglobulin catabolism. Nature, 203, 1352-1355.
78. Jones, A.J. et al. (2007) Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal Nacetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology, 17, 529-540.
79. Stork, R. et al. (2008) N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. The Journal of Biological Chemistry, 283, 7804-7812.
80. Hinton, P.R. et al. (2006) An engineered human IgG1 antibody with longer serum half-life. Journal of Immunology, 176, 346-356.
81. Bitonti, A.J. and Dumont, J.A. (2006) Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Advanced Drug Delivery Reviews, 58, 1106-1118.
82. Parekh, R.B. et al. (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature, 316, 452-457.
83. Axford, J.S. et al. (2003) Rheumatic disease differentiation using immunoglobulin G sugar printing by high density electrophoresis. The Journal of Rheumatology, 12, 2540-2546.
84. Flogel, M. et al. (1998) Fucosylation and galactosylation of IgG heavy chains differ between acute and remission phases of juvenile chronic arthritis. Clinical Chemistry and Laboratory Medicine, 36, 99-102.
85. Go, M.F., Schrohenloher, R.E., and Tomana, M. (1994) Deficient galactosylation of serum IgG in inflammatory bowel disease: correlation with disease activity. Journal of Clinical Gastroenterology, 18, 86-87.
86. Holland, M. et al. (2002) Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clinical and Experimental Immunology, 29, 183-190.
87. Cremata, J.A., Sorell, L. and Montesino, R. (2003) Hypogalactosylation of serum IgG in patients with coeliac disease. Clinical and Experimental Immunology, 133, 422-429.
88. Novak, J. et al. (2005) Heterogeneity of IgG glycosylation in adult periodontal disease. Journal of Dental Research, 84, 897-901.
89. Mizouchi, T. et al. (1982) Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. Journal of Immunology, 129, 2016-2020.
90. Kaneko, Y., Nimmerjahn, F. and Ravetch, J. (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313, 670-673.
91. Jefferis, R. (2006) A sugar switch for antiinflammatory antibodies. Nature Biotechnology, 24, 1230-1231.
92. Scallon, B. et al. (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Molecular Immunology, 44, 1524-1534.
93. Huang, L. et al. (2006) Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. Analytical Biochemistry, 349, 197-207.
94. Qian, J. et al. (2007) Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Analytical Biochemistry, 364, 8-18.
95. Sethuraman, N. and Stadheim, T.A. (2006) Challenges in therapeutic glycoprotein production. Current Opinion in Biotechnology, 17, 341-346.
96. Werner, R.G., Kopp, K., Schleuter, M. (2007) Glycosylation of therapeutic proteins in different production systems. Acta Paediatrica (Oslo, Norway: 1992) Supplement, 96, 17-22.
97. Maenaka, K. et al. (2001) The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. The Journal of Biological Chemistry, 276, 44898-44904.
98. Wormald, M.R. et al. (1997) Variations in oligosaccharide-protein interactions in immunoglobulin G determine the sitespecific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry, 36, 1370-1380.
99. Kumpel, B.M. (2007) Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sanguinis, 93, 99-111.
100. Groenink, J. et al. (1996) On the interaction between agalactosyl IgG and Fc gamma receptors. European Journal of Immunology, 26, 1404-1407.
101. Boyd, P.N. et al. (1995) The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Molecular Immunology, 32, 1311-1318.
102. http://www.fda.gov/cder/biologics/review/ritugen112697-r2.pdf. Accessed January 5th 2009.
103. Garred, P. et al. (2000) Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. The Journal of Rheumatology, 27, 26-34.
104. Saevarsdottir, S., Vikingsdottir, T. and Valdimarsson, H. (2004) The potential role of mannan-binding lectin in the clearance of self-components including immune complexes. Scandinavian Journal of Immunology, 60, 23-29.
105. Taylor, M.E. and Drickamer, K. (2003) Structure-function analysis of C-type animal lectins. Methods in Enzymology, 363, 3-16.
106. Napper, C.E. and Taylor, M.E. (2004) The mannose receptor fails to enhance processing and presentation of a glycoprotein antigen in transfected fibroblasts. Glycobiology, 14, 7C-12C.
107. Cambi, A. and Figdor, C.G. (2003) Levels of complexity in pathogen recognition by C-type lectins. Current Opinion in Cell Biology, 2003, 15, 539-546.
108. Lifely, M.R., Hale, G. and Boyse, S. (1995) Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology, 5, 813-822.
109. Umana, P. et al. (1999) Engineered glycoforms of an anti-neuroblastoma. IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnology, 17, 176-180.
110. Davies, J. et al. (2001) Expression of GTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies of altered glycoforms leads to an increase in ADCC thro' higher affinity for FcRIII. Biotechnology and Bioengineering, 74, 288-294.
111. Shields, R.L. et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. The Journal of Biological Chemistry, 277, 26733-26740.
112. Shinkawa, T. et al. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. The Journal of Biological Chemistry, 278, 3466-3473.
113. Okazaki, A. et al. (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. Journal of Molecular Biology, 336, 1239-1249.
114. Ferrara, C. et al. (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and coexpression of heterologous beta1, 4-Nacetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnology and Bioengineering, 93, 851-861.
115. Niwa, R. et al. (2005) IgG subclassindependent improvement of antibodydependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. Journal of Immunological Methods, 306, 151-160.
116. Natsume, A. et al. (2005) Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. Journal of Immunological Methods, 306, 93-103.
117. Radaev, S. and Sun, P.D. (2001) Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. The Journal of Biological Chemistry, 276, 16478-16483.
118. Suzuki, E. et al. (2007) A nonfucosylated anti-HER2 antibody augments antibodydependent cellular cytotoxicity in breast cancer patients. Clinical Cancer Research, 13, 1875-1882.
119. Youings, A. et al. (1996) Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. The Biochemical Journal, 314, 621-630.
120. Dunn-Walters, D.K., Boursier, L. and Spencer, J. (2000) Effect of somatic hypermutation on potential Nglycosylation sites in human immunoglobulin heavy chain variable regions. Molecular Immunology, 37, 107-113.
121. Harvey, D.J. et al. (2008) Differentiation between isomeric triantennary N-linked glycans by negative ion tandem mass spectrometry and confirmation of glycans containing galactose attached to the bisecting (beta1-4-GlcNAc) residue in Nglycans from IgG. Rapid Communications in Mass Spectrometry, 22, 1047-1052.
122. Chung, C.H. et al. (2008) Cetuximabinduced anaphylaxis and IgE specific for galactose-a-1,3-galactose. The New England Journal of Medicine, 358, 1109-1117.
123. Wright, A. and Morrison, S.L. (1997) Effect of glycosylation on antibody function: implications for genetic engineering. Trends in Biotechnology, 15, 26-32.
124. Gala, F.A. and Morrison, S.L. (2004) V region carbohydrate and antibody expression. Journal of Immunology, 172, 5489-5494.
125. Co, M.S. et al. (1993) Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Molecular Immunology, 30, 1361-1367.
126. Fujomura, Y. et al. (2004) Antigen binding of an ovomucoid-specific antibody is affected by a carbohydrate chain located on the light chain variable region. Bioscience, Biotechnology, and Biochemistry, 64, 2298-2305.
127. Leibiger, H. et al. (1999) Variable domainlinked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding. The Biochemical Journal, 338, (Pt 2) 529-538.
128. Radcliffe, C.M. et al. (2007) Human follicular lymphoma cells contain oligomannose glycans in the antigenbinding site of the B-cell receptor. The Journal of Biological Chemistry, 282, 7405-7415.
129. McCann, K.J. et al. (2008) Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Molecular Immunology, 45, 1567-1572.
130. Weiner, G.J. (2007) Monoclonal antibody mechanisms of action in cancer. Immunologic Research, 39, 271-278.
131. Siberil, S. et al. (2007) FcgR, the key to optimize therapeutic antibodies? Critical Reviews in Oncology/Hematology, 62, 26-33.
132. Congy-Jolivet, N. et al. (2007) Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Critical Reviews in Oncology/Hematology, 64, 226-233.
133. Furst, D.E. et al. (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Annals of the Rheumatic Diseases, 66, (Suppl 3) iii2-iii22.
134. Holland, M. et al. (2004) Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clinical and Experimental Immunology, 138, 183-192.
135. van der Neut Kolfschoten, M. et al. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science, 317, 1554-1557.
136. Nada, A. and Somberg, J. (2007) First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. American Journal of Therapeutics, 14, 594-604.
137. Dayan, C.M. and Wraith, D.C. (2008) Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Clinical and Experimental Immunology, 151, 231-234.
138. Birch, J.R. and Racher, A.J. (2006) Antibody production. Advanced Drug Delivery Reviews, 58, 671-685.
139. Farid, S.S. (2006) Established bioprocesses for producing antibodies as a basis for future planning. Advances in Biochemical Engineering/Biotechnology, 101, 1-42.
140. Mirik, G.R. et al. (2004) A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Quarterly Journal of Nuclear Medicine and Molecular, Imaging 48, 251-257.
141. Sparrow, P.A. (2007) Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Research, 16, 147-161.
142. Gasser, B. and Mattanovitch, D. (2007) Antibody production with yeasts and filamentous fungi: on the road to large scale? Biotechnology Letters, 29, 201-212.
143. Humphreys, D.P. (2003) Production of antibodies and antibody fragments in Escherichia coli and a comparison of their functions, uses and modification. Current Opinion in Drug Discovery & Development, 6, 188-196.
144. Kourti, T. (2006) The Process Analytical Technology initiative and multivariate process analysis, monitoring and control. Analytical and Bioanalytical Chemistry, 384, 1043-1048.
145. http://www.fda.gov/CDER/GUIDANCE/6419fnl.htm. Accessed January 5th 2009.
146. http://www.percivia.com/index.html. Accessed January 5th 2009.
147. Hamilton, S.R. and Gerngross, T.U. (2007) Glycosylation engineering in yeast: the advent of fully humanized yeast. Current Opinion in Biotechnology, 18, 387-392.
148. Cox, K.M. et al. (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nature Biotechnology, 24, 1591-1597.